In addition to showing that usage of Prostatype® at the time of diagnosis would have prompted reclassification of 39% of the patients, the study also showed the following:
- Prostatype® can predict progression, i.e. predict which of the patients that need curative treatment immediately upon diagnosis and who are therefore not suitable for active monitoring.
- Prostatype® confirms the cases in which it may be appropriate to postpone curative treatment for some men with low-risk prostate cancer.
The results from the study will, as previously communicated, be presented at the annual meeting of the
"The strong positive final results in this Spanish multicentre study, which is in line with previously announced interim results, provides further scientific support for the great benefits of using Prostatype® as a decision basis when selecting treatment type for patients with diagnosed prostate cancer. We therefore expect that several Spanish urologists, that have shown great interest but previously waited for the time being, now will begin to use the test in their clinical practices," says
Based on the very positive results, the
For further information about
Telephone: +46 (0) 73 049 77 01
Email: fredrik.persson@prostatypegenomics.com
About
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at
Media enquiries
fredrik.persson@prostatypegenomics.com
Certified Advisor
https://news.cision.com/prostatype-genomics-ab/r/prostatype-genomics-announces-strong-positive-final-results-from-multicentre-study-with-prostatype--,c3962550
(c) 2024 Cision. All rights reserved., source